196 related articles for article (PubMed ID: 19185050)
1. Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.
Chianese-Bullock KA; Lewis ST; Sherman NE; Shannon JD; Slingluff CL
Vaccine; 2009 Mar; 27(11):1764-70. PubMed ID: 19185050
[TBL] [Abstract][Full Text] [Related]
2. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
3. Getting peptide vaccines to work: just a matter of quality control?
Celis E
J Clin Invest; 2002 Dec; 110(12):1765-8. PubMed ID: 12488425
[No Abstract] [Full Text] [Related]
4. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
5. Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
Stephens AJ; Burgess-Brown NA; Jiang S
Front Immunol; 2021; 12():696791. PubMed ID: 34276688
[TBL] [Abstract][Full Text] [Related]
6. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
7. Peptide vaccine.
Izumoto S
Adv Exp Med Biol; 2012; 746():166-77. PubMed ID: 22639167
[TBL] [Abstract][Full Text] [Related]
8. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
Slingluff CL
Cancer J; 2011; 17(5):343-50. PubMed ID: 21952285
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines in breast cancer: The immunological basis for clinical response.
Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
[TBL] [Abstract][Full Text] [Related]
10. Peptide-Based Treatment: A Promising Cancer Therapy.
Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
[TBL] [Abstract][Full Text] [Related]
11. Identification of melanoma-specific peptide epitopes by HLA-A2.1-restricted cytotoxic T lymphocytes.
Ge HL; Wang Y; Wang SJ; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2006 Feb; 38(2):110-8. PubMed ID: 16474902
[TBL] [Abstract][Full Text] [Related]
12. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
13. VaccImm: simulating peptide vaccination in cancer therapy.
von Eichborn J; Woelke AL; Castiglione F; Preissner R
BMC Bioinformatics; 2013 Apr; 14():127. PubMed ID: 23586423
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors.
Jalali SA; Parmiani G
Recent Pat Biotechnol; 2011 Aug; 5(2):108-17. PubMed ID: 21707528
[TBL] [Abstract][Full Text] [Related]
15. Improving the efficacy of peptide vaccines in cancer immunotherapy.
Zahedipour F; Jamialahmadi K; Zamani P; Reza Jaafari M
Int Immunopharmacol; 2023 Oct; 123():110721. PubMed ID: 37543011
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability.
Moynihan KD; Holden RL; Mehta NK; Wang C; Karver MR; Dinter J; Liang S; Abraham W; Melo MB; Zhang AQ; Li N; Gall SL; Pentelute BL; Irvine DJ
Cancer Immunol Res; 2018 Sep; 6(9):1025-1038. PubMed ID: 29915023
[TBL] [Abstract][Full Text] [Related]
18. Peptides as tools and drugs for immunotherapies.
Beck A; Klinguer-Hamour C; Bussat MC; Champion T; Haeuw JF; Goetsch L; Wurch T; Sugawara M; Milon A; Van Dorsselaer A; Nguyen T; Corvaïa N
J Pept Sci; 2007 Sep; 13(9):588-602. PubMed ID: 17602441
[TBL] [Abstract][Full Text] [Related]
19. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
20. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
